Burlington, MA – PharmaEssentia Corporation has announced the appointment of Eric Vogel as U.S. Head of Commercialization. About PharmaEssentia Corporation: PharmaEssentia Corporation is a fully integrated biopharmaceutical company focused on bringing new therapies to patients with myeloproliferative neoplasms (MPNs) and other hematologic cancers. The company is committed to being a leader in MPNs, highlighted by an approved product for adults with polycythemia vera (PV) and ongoing clinical programs for essential thrombocythemia (ET) and early myelofibrosis. PharmaEssentia positions itself as an innovator developing effective new biologic medicines to address critical unmet needs in hematology and oncology, aiming to improve outcomes for people living with challenging blood cancers. With operations in the United States and locations across Asia, the company describes itself as a truly global biopharmaceutical organization pursuing pioneering innovations for the treatment of hematological diseases. Through its research, clinical development, and patient-focused resources, PharmaEssentia seeks to advance the standard of care and establish a strong presence in the specialized market for MPN and hematologic cancer therapies.

For more information visit: https://us.pharmaessentia.com/

PharmaEssentia Corporation
35 Corporate Dr Suite 325
Burlington, MA 1803
Phone: 617-245-2200
LinkedIn: https://www.linkedin.com/company/pharmaessentia-corporation/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved